Clinical Trial Update: Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix® [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing long-term persistence of hepatitis A antibodies after Havrix vaccination 21-25 years earlier has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A

Drugs mentioned

• Havrix (hepatitis A vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis A | Phase 4 | Status: WITHDRAWN